SEC Form 3 · accession 0001213900-17-008215
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hilla Eisenberg
Officer — CFO, Treasurer and Secretary
Period of report
Aug 1, 2017
Accepted (ET)
Aug 3, 2017 · 6:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | holding | — | — | — | 1,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.77 | holding | — | — | — | — | Jun 30, 2027 | Common Stock | 4,500 | — | D |
| Stock Option (Right to Buy)F2 | $8.57 | holding | — | — | — | — | Jul 19, 2027 | Common Stock | 20,001 | — | D |
Explanation of responses
- F1The Stock Option will vest in 3 equal installments of 1,500 on each of December 31, 2017, December 31, 2018 and December 31, 2019.
- F2The Stock Option will vest in 3 equal installments of 6,667 on each of December 31, 2017, December 31, 2018 and December 31, 2019.